Eli Lilly finished an early safety study testing its oral GLP-1 pill, orforglipron, in people with kidney problems. This matters if you have kidney disease and have wondered whether GLP-1 drugs work safely for you, since this group is often left out of trials until after a drug already has approval and coverage decisions in place. The study cleared an early safety hurdle, but that is only one step. No approval exists yet, and no insurance coverage has changed as a result.
The study was a Phase 1 trial, meaning it tested a single dose of orforglipron in a small group of participants, some with normal kidney function and some with kidney impairment, mainly to check safety rather than prove the drug works well for weight loss or blood sugar control in this population. Passing this stage means Lilly can move toward larger trials that would test the drug over longer periods and in more people with kidney disease. Those later trials, plus FDA review, still need to happen before any approval decision is made. Insurance coverage decisions typically follow approval, so even if later trials go well, coverage for people with kidney disease could take additional time to sort out. For now, this result simply means kidney patients were not automatically excluded from the research process, which is different from having a treatment option available to them.
If you have kidney disease and currently use a GLP-1 medication, this news does not change your treatment options or your coverage today. It is a signal that Lilly is building the safety data needed to eventually seek approval for this group, but the timeline from here to an approved, covered treatment is still long. I would suggest continuing to work with your doctor on your current care plan and asking directly whether your insurance covers any GLP-1 options for your specific kidney function. Keep an eye on later trial results and FDA actions as they come, since those are the steps that actually change what is available to you.
Key details
Lilly's pill passed an early kidney safety test, but no approval or coverage exists yet.
Read this on GLP1Laws: https://glp1laws.com/patient-lens/access-roundup-2026-06-08